SCHEMBL25877960

SCHEMBL25877960

CC(=O)Nc1cc(N)c(NC2(C)COC2)cn1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.41
PIK3C3 Q8NEB9 7/20 0.37
PTK2 Q05397 1/20 0.37
CYP1A2 P05177 1/20 0.37
GAA P10253 1/20 0.37
MAPK8 P45983 5/20 0.36
MAPK9 P45984 4/20 0.36
PRKD3 O94806 1/20 0.36
MAP4K4 O95819 1/20 0.36
MAPK10 P53779 1/20 0.36
MAP4K2 Q12851 1/20 0.36
PKN2 Q16513 1/20 0.36
PRKD2 Q9BZL6 1/20 0.36
STK17A Q9UEE5 1/20 0.36
HTR1A P08908 1/20 0.35
HTR1D P28221 1/20 0.35
HTR1F P30939 1/20 0.35
PIK3R1 P27986 1/20 0.35
PIK3CA P42336 1/20 0.35
MTOR P42345 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25877966 0.80 CYP1A2 (0.48) L3MBTL1CYP1A2GAASMN1; SMN2
SCHEMBL25877777 0.77 LATS1 (0.32)
SCHEMBL24141266 0.76 L3MBTL1 (0.40) L3MBTL1PIK3C3PTK2CYP1A2GAA
SCHEMBL24140935 0.75 HDAC1 (0.45) CYP1A2
SCHEMBL30755915 0.71 HTR1F (0.48) L3MBTL1PIK3C3PTK2MAPK8MAPK9
SCHEMBL623368 0.71 L3MBTL1 (0.53) L3MBTL1PIK3C3PTK2CYP1A2GAA
Hydrochloric Acid SCHEMBL31492961 0.70 HTR1F (0.47) L3MBTL1PIK3C3PTK2MAPK8MAPK9
SCHEMBL24140926 0.70 ALDH1A1 (0.40) GAANPC1RAB9ASMN1; SMN2
SCHEMBL18397392 0.70 L3MBTL1 (0.52) L3MBTL1PIK3C3PTK2CYP1A2GAA
Hydrochloric Acid SCHEMBL32667175 0.70 L3MBTL1 (0.52) L3MBTL1PIK3C3PTK2CYP1A2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230234943-A1 TREX1 INHIBITORS AND USES THEREOF TEMPEST THERAPEUTICS, INC. 2023-07-27 US disclosed
US-20230234943-A1 TREX1 INHIBITORS AND USES THEREOF TEMPEST THERAPEUTICS, INC. 2023-07-27 US disclosed
US-20230234943-A1 TREX1 INHIBITORS AND USES THEREOF TEMPEST THERAPEUTICS, INC. 2023-07-27 US disclosed
WO-2021263079-A1 TREX1 INHIBITORS AND USES THEREOF TEMPEST THERAPEUTICS, INC. (US) 2021-12-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230234943-A1 TREX1 INHIBITORS AND USES THEREOF FEN1, ERCC4, DCLRE1B L3MBTL1 2452/4885PIK3C3 699/4885PTK2 4764/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.